Guangying Du

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1952730/publications.pdf

Version: 2024-02-01

15 papers	156 citations	1307594 7 h-index	1125743 13 g-index
15 all docs	15 docs citations	15 times ranked	341 citing authors

#	Article	IF	Citations
1	Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model. International Journal of Immunopathology and Pharmacology, 2017, 30, 215-226.	2.1	33
2	PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models. International Journal of Immunopathology and Pharmacology, 2018, 32, 205873841878799.	2.1	23
3	PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice. PLoS ONE, 2020, 15, e0228339.	2.5	22
4	Human IL18-IL2 fusion protein as a potential antitumor reagent by enhancing NK cell cytotoxicity and IFN-Î³ production. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1727-1736.	2.5	15
5	NSK-01105, a Novel Sorafenib Derivative, Inhibits Human Prostate Tumor Growth via Suppression of VEGFR2/EGFR-Mediated Angiogenesis. PLoS ONE, 2014, 9, e115041.	2.5	13
6	Determination of kynurnine and tryptophan, biomarkers of indoleamine 2,3-dioxygenase by LCâ€“MS/MS in plasma and tumor. Bioanalysis, 2018, 10, 1335-1344.	1.5	12
7	PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer. Toxicology and Applied Pharmacology, 2020, 398, 115019.	2.8	12
8	Preparation, Pharmacokinetics, Biodistribution, Antitumor Efficacy and Safety of Lx2-32c-Containing Liposome. PLoS ONE, 2014, 9, e114688.	2.5	6
9	Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects. International Journal of Immunopathology and Pharmacology, 2020, 34, 205873842095058.	2.1	5
10	Improving the treatment of Parkinson's disease: Structure-based development of novel 5-HT2A receptor antagonists/inverse agonists. European Journal of Medicinal Chemistry, 2022, 234, 114246.	5.5	5
11	PCC0208018 exerts antitumor effects by activating effector T cells. International Journal of Immunopathology and Pharmacology, 2019, 33, 205873841984336.	2.1	4
12	Synthesis and analysis of dihydrotetrabenazine derivatives as novel vesicular monoamine transporter 2 inhibitors. European Journal of Medicinal Chemistry, 2021, 224, 113718.	5.5	3
13	Pharmacokinetics of S-EPA, and its inhibition on indoleamine 2,3-dioxgenase: a case of sulfur-substitution affecting distributions in blood cells. Xenobiotica, 2019, 49, 1338-1343.	1.1	2
14	(+)-9-Trifluoroethoxy-Î±-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia. Frontiers in Pharmacology, 2021, 12, 770377.	3.5	1
15	9-Cyclopropylmethoxy-dihydrotetrabenazine and its stereoisomers as vesicular monoamine transporter-2 inhibitors. Future Medicinal Chemistry, 2022, 14, 991-1003.	2.3	0